



PRESS RELEASE

875 Ellicott Street • Buffalo, NY 14203 • 716/888-4800 • www.jacobsinstitute.org

Embargoed until 12:00pm, April 27, 2021

Contact:

Allison Kupferman

Director, Communications & Outreach

Mobile: 703-969-3001

E-mail: akupferman@jacobsinstitute.org

Dr. Adnan Siddiqui Announced as New Jacobs Institute Chief Executive Officer

BUFFALO, N.Y., April 27, 2021—The Jacobs Institute (JI), a non-profit medical device innovation center, announced today that Adnan H. Siddiqui, MD, PhD, FACS, FAHA, FAANS, was confirmed by the JI Board of Directors as the new Chief Executive Officer. Siddiqui will also maintain his current role as Chief Medical Officer with the organization, overseeing clinical innovation. A search process for a newly created Chief Operating Officer position is underway and the Institute anticipates announcing this in the coming months. The organization has grown to 29 employees over the past several years.

Dr. Siddiqui joined the JI team as Chief Medical Officer in 2016, and replaces former CEO, Bill Maggio, whose retirement from the JI was announced in early April. Mr. Maggio will continue to serve as a Senior Advisor to the CEO. During Dr. Siddiqui's time as CMO, he has attracted global medical device companies to bring hundreds of their engineers and sales representatives to Buffalo for clinical training programs; drawn entrepreneurs and start-ups from the local area and Silicon Valley to accelerate their medical device technology development with JI's i2R, or idea to Reality Center; and was integral in recruiting former U.S. Food and Drug Administration Office Director Dr. Carlos Peña to be the JI's Chief Regulatory Officer.

Dr. Siddiqui shared, "This is an opportunity of a lifetime. I am deeply appreciative of the endorsement by the JI Board. I am excited to be a part of advancing Dr. Nick Hopkins vision—our Founder and my mentor. My goal is to assist him and the JI team in developing innovative technologies to tackle vascular disease, a major cause of morbidity and mortality in Western New York and the world. We have incredibly talented physicians, researchers and engineers working together in a uniquely collaborative ecosystem designed for creativity and innovation. The JI partnerships with the University at Buffalo, Kaleida Health's Gates Vascular Institute, and our corporate clients—which include inventors, entrepreneurs, and companies from all over the world—makes it highly likely that the next big development to impact stroke and vascular disease comes out of Buffalo. We are now the recognized global destination for vascular medical device innovation. The JI is committed to advancing Buffalo as the med tech hub for innovation. I am dedicated to our vision of improving the lives of patients suffering from debilitating vascular diseases while fostering regional economic development and honoring Dr. Larry Jacobs."

Jacobs Institute Chairman of the Board, Mr. Jeremy M. Jacobs, said, "Dr. Siddiqui has a six-year history as Chief Medical Officer overseeing clinical innovation at the Institute. He was integral in establishing the JI's reputation among physicians and vascular medical device companies around the globe. His familiarity with the leadership and staff positions him well for this new responsibility. Dr. Siddiqui is a solid successor in the CEO role, and he has my full support."

Dr. Siddiqui is also vice-chairman and professor of neurosurgery at the University at Buffalo (UB). Dr. Siddiqui is director of neurosurgical stroke service at Kaleida Health's Gates Vascular Institute (GVI), director of the neuroendovascular fellowship program at UB, and director of the UB Canon Stroke and Vascular Research Center. He was nominated as a co-chair for the Devices for Acute Ischemic Stroke Intervention (DAISI) a Coordinated Registry network run collaboratively by the U.S. Food and Drug Administration (FDA), Centers for Medicare and Medicaid Services (CMS), and National Institutes of Health (NIH) with partnership with physician societies and industry. Dr. Siddiqui also recently assumed the role of co-chair of the Neurological Devices Working group for the Medical Device Industry Consortium (MDIC), a not-for-profit group consisting of FDA, CMS, and industry partners dedicated to resuming Early Feasibility Studies (EFS) also known as First in Human studies in the U.S.

He completed fellowship training in interventional neuroradiology, cerebrovascular surgery, and neurocritical care from Thomas Jefferson University in Philadelphia. He completed his neurosurgical residency at Upstate Medical University and received his PhD in neuroscience from the University of Rochester and medical degree from Aga Khan University in Pakistan.

###

About the Jacobs Institute

The Jacobs Institute is a non-profit organization whose mission is to accelerate the development of next-generation technologies in vascular medicine through collisions of physicians, engineers, entrepreneurs, and industry. The JI's vision is to improve the treatment of vascular disease in Western New York and the world, while fostering local economic development. The JI fosters medical collaboration and innovation through partnerships with the University at Buffalo (UB), Kaleida Health, and industry, to be a fitting tribute to the work and memory of Lawrence D. Jacobs, M.D.

To learn more about the Jacobs Institute, please visit our website at: <https://jacobsinstitute.org>.

Dr. Siddiqui's full biography is included below, or you may visit our staff page here: <https://jacobsinstitute.org/the-jacobs-institute/staff/#staff-auto-draft>

Adnan H. Siddiqui, MD, PhD, FACS, FAHA, FAANS
Chief Executive Officer & Chief Medical Officer
Jacobs Institute

Dr. Adnan H. Siddiqui is chief executive officer & chief medical officer of the Jacobs Institute (JI). His goal is to improve the JI's current offerings and translate technologies being developed in the Institute's i2R, or idea to Reality Center, into therapeutic and commercial successes.

Dr. Siddiqui is also vice-chairman and professor of neurosurgery at the State University of New York at Buffalo (UB) Jacobs School of Medicine and Biomedical Sciences. He is the director of the neurosurgical stroke service at Kaleida Health's Gates Vascular Institute (GVI), director of the neuroendovascular fellowship program at UB, and director of the UB Canon Stroke and Vascular Research Center. He is also a practicing surgeon with the University at Buffalo Neurosurgery (UBNS) clinical practice, where he sees and treats patients.

He completed fellowship training in interventional neuroradiology, cerebrovascular surgery, and neurocritical care from Thomas Jefferson University in Philadelphia. He completed his neurosurgical residency at Upstate Medical University and received his PhD in neuroscience from the University of Rochester and medical degree from Aga Khan University in Pakistan. He is a fellow of the American Association of Neurological Surgeons (AANS), American College of Surgeons (ACS), and American Heart Association (AHA), and member of the Society of Neurological Surgeons (Senior Society) and Academy of Neurological Surgeons (the Academy).

Dr. Siddiqui has over 450 peer reviewed publications, more than 50 chapters, almost 70,000 citations and an H index of 72. He is particularly proud of representing Buffalo and the U.S. at most major cerebrovascular conferences around the world with over 200 international presentations to date. He has designed, conducted, and lead multiple major national and international clinical trials and currently serves as national and international principal investigator (PI) for multiple major funded multi-site trials. These efforts have significantly contributed to the success of the department, which was ranked 7th in academic impact in North America by the *Journal of Neurosurgery*.

He also serves as director of the Canon Stroke and Vascular Research Center (CSVRC) at UB. This multi-disciplinary center, with multiple concurrent major NIH grants, houses neurosurgeons, neuroscientists, physicists and biomedical engineers working collaboratively on cutting edge research focused on neurovascular biology and pathology including stroke and aneurysms, imaging, simulation, and hemodynamics. He is the Fellowship Director for Buffalo's prestigious Neuroendovascular Program. In addition, he serves as the director of the Neurosurgical Stroke Service at the GVI, one of the busiest Comprehensive Stroke Services in New York State and the U.S.

Dr. Siddiqui has continuously served on multiple scientific and educational committees of AANS, Congress of Neurological Surgeons (CNS) and Society of NeuroInterventional Surgery (SNIS). He is the chairman of the Joint Section of Cerebrovascular Surgery of the AANS and CNS and secretary for the SNIS. It has been a major focus for him to achieve consensus between the various organizations involved in fellowship training and credentialing for Neuroendovascular Surgery. He was a founding member of the Neuroendovascular Surgery Advisory Committee (NESAC) for Society of Neurological Surgery's Committee for Advanced Sub-Specialty Training (CAST) and currently is a member of the American Board of Neurological Surgery's (ABNS) Central Nervous System Endovascular Surgery Advisory Committee (CESAC). This has been an extremely important role, which is profoundly affecting the training and education pathways of neuroendovascular specialists.

He serves as a neurosurgeon director on the executive committee of the SNIS Patient Safety Organization which runs the NVQI-QOD Quality Outcomes Registry. He was nominated as a co-chair for the Devices for Acute Ischemic Stroke

Intervention (DAISI) a Coordinated Registry network run collaboratively by the U.S. Food and Drug Administration (FDA), Centers for Medicare and Medicaid Services (CMS), and NIH with partnership with physician societies and industry. He is committed to this singular opportunity to unify the multi-specialty neuroendovascular surgery field to develop robust prospective quality outcomes databases to shepherd the next generation of evidence-based practice. Recently, he has assumed the role of co-chair of the Neurological Devices Working group for the Medical Device Industry Consortium (MDIC), a not-for-profit group consisting of FDA, CMS, and industry partners dedicated to resuming Early Feasibility Studies (EFS) also known as First in Man studies in the U.S.

Dr. Siddiqui has special interest and expertise in the performance of complementary microsurgical, radiosurgical, and endovascular techniques for the comprehensive management of cerebrovascular conditions. This spectrum of disease includes aneurysms and arteriovenous malformations, as well as dural, cavernous, and spinal fistulae. He has special interests in endovascular management of acute ischemic stroke, as well as endovascular and microsurgical management of extracranial and intracranial vascular occlusive disease. Other clinical interests include endovascular management of intractable epistaxis, facial vascular malformations, head, neck, and brain tumor embolization, and microsurgical resection of skull base tumors. He is profoundly indebted to his mentors Nick Hopkins, Robert Rosenwasser, Charles Hodge, and Shirley Joseph in shaping his career as a dual-trained cerebrovascular surgeon, clinician scientist and entrepreneur.

All these efforts as a microsurgeon, endovascular surgeon, scientist, and trialist, have allowed Dr. Siddiqui to gain unique insights into a critical and rapidly evolving specialty. At the same time, these endeavors have required significant collaborations resulting in strong and trusting relationships with fellow neurosurgeons, neurologists, neuroradiologists, scientists, engineers, regulatory officers, and industry.

Dr. Siddiqui is married and has three children. He is a proud Buffalonian who is challenged and invigorated by taking care of neurosurgical patients and their families. He is most gratified by his pedagogical responsibilities, which allow him the opportunity to teach medical students, residents, and fellows. He is grateful for the opportunity to work at UB's Department of Neurosurgery, CSVRC, GVI, and JI facilities, with some of the world's best technologies and greatest vascular specialists, researchers, and biomedical engineers who are collaborating to advance the care of vascular diseases.